OKYO Pharma to Present at Stifel Healthcare Conference
The clinical-stage biopharmaceutical company will take part in the Stifel 2026 Healthcare Conference from November 10 to 12, 2026.
Updated on Nov. 5, 2026 in Healthcare
OKYO Pharma Limited will participate in the Stifel 2026 Healthcare Conference November 10-12, 2026, held at the Lotte New York Palace Hotel in New York. Chief Executive Officer Robert J. Dempsey is scheduled to present at 9:20 a.m. ET on Thursday, November 12.
Why it matters
The appearance gives investors and analysts a direct opportunity to hear from company leadership about OKYO's development programs. OKYO leadership will also be available for one-on-one investor meetings throughout the conference, which is held in New York City.
The company's CEO is scheduled to present at 9:20 a.m. ET on November 12, 2026, and the webcast will be archived for 90 days following the conference. The source does not disclose what operational or financial updates will be shared during the presentation.
The players
OKYO Pharma Limited
OKYO Pharma is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.
Robert J. Dempsey
Robert J. Dempsey is the Chief Executive Officer of OKYO Pharma, leading the company's clinical development efforts.
The details
OKYO Pharma, a clinical-stage company developing therapies for neuropathic corneal pain and anterior segment eye diseases, will attend the Stifel 2026 Healthcare Conference. A live webcast of the presentation will be available through Stifel Live Webcast, and investors interested in one-on-one meetings should contact their Stifel representative.
Timeline
November 10-12, 2026: Stifel 2026 Healthcare Conference, in which OKYO Pharma participates.
November 12, 2026, 9:20 a.m. ET: Scheduled presentation by CEO Robert J. Dempsey.
Following the conference: Webcast archived for 90 days on the OKYO Pharma website.
Pipeline Context
The conference appearance follows the first patient enrollments announced in the Phase 3 NEPTUNE trial for urcosimod, OKYO's lead candidate for neuropathic corneal pain. The presentation offers investors an update on the company's position as it advances this late-stage program.
Investors who want direct access to OKYO leadership can request a one-on-one meeting through their Stifel representative during the conference. Those unable to attend can watch the live webcast or view the archived version for 90 days on the OKYO Pharma website.
The takeaway
Investors following OKYO Pharma can use the conference webcast and archived replay to track updates on urcosimod and the NEPTUNE trial without attending in person. Scheduling a one-on-one meeting through a Stifel representative offers the most direct route to management access.
What happens next
OKYO Pharma's CEO presentation is scheduled for 9:20 a.m. ET on November 12, 2026, during the Stifel 2026 Healthcare Conference.
Further reading
For more on the sector, browse Healthcare coverage in New York City.
Source note: This article includes information reported by The Manila times.
